This listing of the claims will replace all prior versions, and listings, of claims in the application:

LISTING OF THE CLAIMS

Claim 1 (currently amended): A therapeutic composition comprising a solid porous matrix comprising ~~random aggregates of~~ a ~~polysorbate~~ surfactant and a therapeutic.

Claim 2 (currently amended): The ~~A~~ therapeutic composition according to claim 1 wherein said composition is in a physical state selected from a dried state and a liquid state.

Claim 3 (currently amended): The ~~A~~ therapeutic composition according to claim 2 wherein said composition is in a liquid state.

Claim 4 (currently amended): The ~~A~~ therapeutic composition according to claim 3 wherein said liquid state further comprises a resuspending medium.

Claim 5 (canceled).

Claim 6 (currently amended): The ~~A~~ therapeutic composition according to claim 4 ~~5~~ wherein said resuspending ~~aqueous~~ medium is selected from the group consisting of water, buffer, physiological saline, and normal saline.

Claim 7 (currently amended): The ~~A~~ therapeutic composition according to claim 1 further comprising an additive selected from the group consisting of polyethylene glycol, sucrose, glucose, fructose, mannose, trehalose ~~trebalose~~, glycerol, propylene glycol and sodium chloride.

Claim 8 (currently amended): The ~~A~~ therapeutic composition according to claim 7 wherein said additive is selected from the group consisting of polyethylene glycol and sucrose.

Claim 9 (currently amended): The ~~A~~ therapeutic composition according to claim 8 wherein said additive is polyethylene glycol.

Claim 10 (currently amended): The ~~A~~ therapeutic composition according to claim 9 wherein said polyethylene glycol is PEG-400.

Claim 11 (currently amended): The ~~A~~ therapeutic composition according to claim 1 wherein said polysorbate surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80.

Claim 12 (currently amended): The ~~A~~ therapeutic composition according to claim 9 wherein said polysorbate surfactant is polysorbate 80.

Claim 13 (currently amended): The ~~A~~ therapeutic composition according to claim 1 wherein said therapeutic is selected from the group consisting of antineoplastic agents, blood products, biological response modifiers, antifungal agents, β-lactam antibiotics, hormones, vitamins, peptides, enzymes, antiallergic agents, anticoagulation agents, circulatory drugs, antituberculars, antivirals, antianginals, antibiotics, antiinflammatories, antiprotozoans, antirheumatics, narcotics, cardiac glycosides, neuromuscular blockers, sedatives, anesthetics, radioactive particles, monoclonal antibodies, and genetic material.

Claim 14 (currently amended): The ~~A~~ therapeutic composition according to claim 13 wherein said antineoplastic agent is selected from the group consisting of platinum compounds, adriamycin, mitomycin, ansamitocin, bleomycin, cytosine arabinoside, arabinosyl adenine, mercaptopolylysine, vincristine, busulfan, chlorambucil, melphalan, mercaptopurine, mitotane, procarbazine hydrochloride, dactinomycin, daunorubicin hydrochloride, doxorubicin hydrochloride, taxol, mitomycin, plicamycin, aminoglutethimide, estramustine phosphate sodium, flutamide, leuprolide acetate, megestrol acetate, tamoxifen citrate, testolactone, trilostane, amsacrine, asparaginase, etoposide, interferon, teniposide, vinblastine sulfate, vincristine sulfate, bleomycin, methotrexate, and carzelesin.

Claim 15 (currently amended): The ~~A~~ therapeutic composition according to claim 14 wherein said antineoplastic agent is taxol.

Claim 16 (currently amended): The ~~A~~ therapeutic composition according to claim 13 wherein said therapeutic is selected from the group consisting of ketoconazole, nystatin, griseofulvin, flucytosine, miconazole, amphotericin B, ricin, and β-lactam antibiotics.

Claim 17 (currently amended): The ~~A~~ therapeutic composition according to claim 16 wherein said therapeutic is amphotericin B.

Claim 18 (currently amended): The ~~A~~ therapeutic composition according to claim 17 wherein said solid porous matrix is between about 100 nm and 2 microns in diameter.

Claim 19 (currently amended): A solid porous matrix comprising a surfactant in combination with a therapeutic prepared by combining a solvent, a surfactant, and a therapeutic to form an emulsion ~~comprising random aggregates~~ of said surfactant and said therapeutic; and processing said emulsion by controlled drying or controlled agitation and controlled drying, to form said solid porous matrix.

Claim 20 (currently amended): The ~~A~~ solid porous matrix according to claim 19 wherein said solvent is evaporated during said processing.

Claims 21-22 (canceled).

Claim 23 (currently amended): The ~~A~~ solid porous matrix according to claim 19 wherein said therapeutic is selected from the group consisting of antineoplastic agents, blood products, biological response modifiers, antifungal agents, β-lactam antibiotics, hormones, vitamins, peptides, enzymes, antiallergic agents, anticoagulation agents, circulatory drugs, antituberculars, antivirals, antianginals, antibiotics, antiinflammatories, antiprotozoans, antirheumatics, narcotics, cardiac glycosides, neuromuscular blockers, sedatives, anesthetics, radioactive particles, monoclonal antibodies, and genetic material.

Claim 24 (currently amended): The ~~A~~ solid porous matrix according to claim 23 wherein said antineoplastic agent is selected from the group consisting of platinum compounds, adriamycin, mitomycin, ansamitocin, bleomycin, cytosine arabinoside, arabinosyl adenine, mercaptopolylysine, vincristine, busulfan, chlorambucil, melphalan, mercaptopurine, mitotane, procarbazine hydrochloride, dactinomycin, daunorubicin hydrochloride, doxorubicin hydrochloride, taxol, mitomycin, plicamycin, aminoglutethimide, estramustine phosphate sodium, flutamide, leuprolide acetate, megestrol acetate, tamoxifen citrate, testolactone, trilostane, amsacrine, asparaginase, etoposide, interferon, teniposide, vinblastine sulfate, vincristine sulfate, bleomycin, methotrexate, and carzelesin.

Claim 25 (currently amended): The ~~A~~ solid porous matrix according to claim 24 wherein said antineoplastic agent is taxol.

Claim 26 (currently amended): The ~~A~~ solid porous matrix according to claim 23 wherein said therapeutic is selected from the group consisting of ketoconazole, nystatin, griseofulvin, flucytosine, miconazole, amphotericin B, ricin, and β-lactam antibiotics.

Claim 27 (currently amended): The ~~A~~ solid porous matrix according to claim 26 wherein said therapeutic is amphotericin B.

Claim 28 (currently amended): The ~~A~~ solid porous matrix according to claim 19, having a diameter of between about 100 nm and 2 microns.

Claim 29 (original): A method of preparing a solid porous matrix comprising a surfactant and a therapeutic, said method comprising:

a. combining a solvent, a surfactant, and a therapeutic to form an emulsion comprising random aggregates of said surfactant and said therapeutic; and

b. processing said emulsion by controlled drying, or controlled agitation and controlled drying, to form a solid porous matrix.

Claim 30 (currently amended): The ~~A~~ method according to claim 29, wherein said surfactant is selected from the group consisting of nonionic surfactants, oils, lipids, proteins, polypeptides, polysaccharides, sugars, polymers, and acrylates ~~polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80~~.

Claim 31 (currently amended): The ~~A~~ method according to claim 30 wherein said ~~polysorbate~~ surfactant is a polymer, and is selected from the group consisting of polyglutamic acid, polylysine, polyphosphazene, polyvinylalcohol, polyethyleneglycol, polypropyleneglycol, polylactic acid, poly (ε-caprolactone), polylactide co-glycolide, and polyethylene-polypropyleneglycol ~~polysorbate 80~~.

Claim 32 (currently amended): The ~~A~~ method according to claim 29 wherein said controlled drying is selected from the group consisting of lyophilizing, spray drying, or any combination thereof.

Claim 33 (currently amended): The ~~A~~ method according to claim 29 further comprising adding said solid porous matrix to a resuspending medium.

Claim 34 (currently amended): The ~~A~~ method according to claim 33 wherein said resuspending medium is selected from the group consisting of an aqueous solution or an organic solution.

Claim 35 (currently amended): The ~~A~~ method of claim 34 wherein said resuspending medium comprises an additive selected from the group consisting of polyethylene glycol, sucrose, glucose, fructose, mannose, trehalose ~~trebalose~~, glycerol, propylene glycol, and sodium chloride.

Claim 36 (currently amended): The ~~A~~ method according to claim 35 wherein said additive is selected from the group consisting of polyethylene glycol and sucrose.

Claim 37 (currently amended): The ~~A~~ method according to claim 36 wherein said additive is polyethylene glycol.

Claim 38 (currently amended): The ~~A~~ method according to claim 37 wherein said polyethylene glycol is PEG-400.

Claim 39 (new): The therapeutic composition according to claim 1 which comprises a solid porous matrix having microvoids comprising a gas.

Claim 40 (new): The therapeutic composition according to claim 39 wherein the gas is selected from the group consisting of air, noble gases, carbon dioxide, nitrogen, fluorine, oxygen, sulfur-based gases and fluorinated gases.

Claim 41 (new): The therapeutic composition of claim 1 wherein said surfactant is selected from the group consisting of nonionic surfactants, oils, lipids, proteins, polypeptides, polysaccharides, sugars, polymers, and acrylates.

Claim 42 (new): The therapeutic composition of claim 41 wherein said surfactant is a polymer selected from the group consisting of polyglutamic acid, polylysine, polyphosphazene, polyvinylalcohol, polyethyleneglycol, polypropyleneglycol, polylactic acid, poly (ε-caprolactone), polylactide co-glycolide, and polyethylene-polypropyleneglycol.

Claim 43 (new): The therapeutic composition according to claim 2 wherein said composition is in a dried state, and is rehydrated with an aqueous solution.

Claim 44 (new): The solid porous matrix according to claim 20 wherein said surfactant is selected from the group consisting of nonionic surfactants, oils, lipids, proteins, polypeptides, polysaccharides, sugars, polymers, and acrylates.

Claim 45 (new): The solid porous matrix according to claim 44 wherein said surfactant is a polymer selected from the group consisting of polyglutamic acid, polylysine, polyphosphazene, polyvinylalcohol, polyethyleneglycol, polypropyleneglycol, polylactic acid, poly (ε-caprolactone), polylactide co-glycolide, and polyethylene-polypropyleneglycol.